Organ systems

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021
Drugs, Steroids, Organ systems, Corticosteroids, Combination drugs, Antipsoriatics, Glucocorticoids, Calcipotriol/betamethasone dipropionate, Betamethasone dipropionate, Betamethasone, Psoriasis, Calcipotriol

"Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.

Key Points: 
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Until now they could not be combinedinto an aqueous cream, which is less greasy and more user-friendly than other formulations."
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Retrieved on: 
Monday, July 19, 2021
Drugs, Steroids, Organ systems, Combination drugs, Corticosteroids, Antipsoriatics, Calcipotriol/betamethasone dipropionate, Betamethasone dipropionate, Betamethasone, Psoriasis, Calcipotriol, Topical steroid

Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.

Key Points: 
  • Now available: Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w0.005%/0.064%) once-daily topical treatment of plaque psoriasis in adults 18 years of age orolderintroduces useof PAD Technology.
  • "Calcipotriene and betamethasone dipropionate are well-established molecules for the treatment ofplaque psoriasis, with proven efficacy, safety and tolerability.
  • Wynzora Cream is based on PADTechnology, which uniquely enables stability of both calcipotriene and betamethasone dipropionate in aconvenient-to-use aqueous formulation.
  • Wynzora (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis inadults.It is notknown ifWynzoraCream is safeand effectivein children.

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

Retrieved on: 
Monday, July 19, 2021
Clinical medicine, Medicine, Organ systems, Anti-acne preparations, Acneiform eruptions, Retinoids, Acne, Puberty, Isotretinoin, Minocycline, Tretinoin, Scar

BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced the initiation of an investigator initiated trial (IIT or study) evaluating the safety and efficacy of AMZEEQ (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne.

Key Points: 
  • BRIDGEWATER, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (VYNE or the Company) today announced the initiation of an investigator initiated trial (IIT or study) evaluating the safety and efficacy of AMZEEQ (minocycline) topical foam, 4%, as a companion treatment with oral isotretinoin in patients with moderate to severe acne.
  • Isotretinoin has been widely used forthe management of severe or scarring acne since its introduction as Accutane in the 1980s.
  • Dr. Lain also served as an investigator in the clinical trials for AMZEEQ and is a consultant to VYNE.
  • AMZEEQ is a valuable topical treatment option for moderate to severe acne.

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

Retrieved on: 
Monday, July 19, 2021
Medical devices, FDA, Health, Diabetes, Pharmaceutical, Biotechnology, Organ systems, Hormones, Endocrine system, Peptide hormones, Animal products, Pancreatic hormones, Glucagon, Diabetes, Hypoglycemia, MHRA, Glucagon, Severe Hypoglycaemia, Xeris Pharmaceuticals, Inc., GLUCAGON, SEVERE HYPOGLYCAEMIA, XERIS PHARMACEUTICALS, INC.

Under the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.

Key Points: 
  • Under the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.
  • Gvoke is indicated for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes ages 2 years and above.
  • The United Kingdoms Medicines and Healthcare products Regulatory Agency (MHRA) approved Ogluo (glucagon) injection on April 29, 2021.
  • Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

TempraMed's VIVI Cap 1 is changing the way people who inject insulin live their lives

Retrieved on: 
Friday, July 16, 2021
Clinical medicine, Branches of biology, Organ systems, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Type 1 diabetes, Injector pen, Insulin pump, Insulin aspart

TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention.

Key Points: 
  • TempraMed's recently launched VIVI Cap 1 is an easy-to-use reusable insulin pen cap that keeps diabetes insulin at a safe temperature 24/7 365 days a year, for years on end without need for any user intervention.
  • From the point of manufacturing up until it is used, insulin needs to be kept between 36 to 46F.
  • During use, insulin does not have to be refrigerated but it should stay below 86F and should not freeze.
  • Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

Retrieved on: 
Thursday, July 15, 2021
Hormones, Endocrine system, Organ systems, Sex hormones, Peptide hormones, Hypogonadotropic hypogonadism, Hypogonadism, Follicle-stimulating hormone, Gonadotropin, Luteinizing hormone, Isolated hypogonadotropic hypogonadism, Testosterone

These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Key Points: 
  • These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
  • Safety and efficacy of JATENZO in males less than 18 years old have not been established.
  • Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled.

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Retrieved on: 
Wednesday, July 14, 2021
Tyrosine kinases, Branches of biology, Signal transduction, Organ systems, Tyrosine kinase 2, Galapagos NV, Psoriasis, Tyrosine kinase, Biology, Janus kinase inhibitor, Janus kinase 3 inhibitor

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.

Key Points: 
  • Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.
  • Galapagos evaluated GLPG3667, a proprietary selective TYK2 compound, in a randomized, placebo-controlled, double-blind Phase 1b study in 31 patients with diagnosis of moderate to severe plaque psoriasis.
  • Main objectives were to evaluate the safety and tolerability of GLPG3667 as well as signs of clinical activity at Week 4.
  • Based on these results, we aim to initiate a global Phase 2b program in psoriasis next year as part of a program to develop our selective oral TYK2 inhibitor GLPG3667 broadly in inflammatory indications.

Global Diabetes Devices and Drugs Market (2020 to 2026) - Industry Analysis, Trends, Market Size, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Diabetes, Pharmaceutical, Health, Medical devices, Health, Forecasting, Statistical forecasting, Supply chain management, Diabetes, Organ systems

The "Diabetes Devices and Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetes Devices and Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global diabetes devices and drugs market provides qualitative and quantitative analysis for the period from 2018 to 2026.
  • The report predicts the global diabetes devices and drugs market to grow with a CAGR of 6.5% over the forecast period from 2020-2026.
  • The report on diabetes devices and drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global diabetes devices and drugs market over the period of 2018 to 2026.

Prostate Cancer Clinical Landscape Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Oncology, Anatomy, Organ systems, Prostate cancer, Chemical compounds, Nonsteroidal antiandrogens, Progonadotropins, Histopathology, Enzalutamide, MCRPC, Prostate, Cancer, Prostvac

In the US, prostate cancer is the most common non-cutaneous malignancy diagnosed in men, and is the second-leading cause of cancer mortality in men behind lung cancer.

Key Points: 
  • In the US, prostate cancer is the most common non-cutaneous malignancy diagnosed in men, and is the second-leading cause of cancer mortality in men behind lung cancer.
  • Prostate cancer drugs, on average, take 9.0 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
  • Pfizer's next-generation androgen receptor (AR) inhibitor Xtandi is the market leader in prostate cancer due to its established efficacy across prostate cancer segmentations and a lack of near-term generic competition.
  • Future expansion opportunities include potential use in combination with PARP inhibitors Talzenna or Rubraca in metastatic castration-resistant prostate cancer (mCRPC) patients.

Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss

Retrieved on: 
Thursday, July 15, 2021
Science, Venture capital, Stem cells, Biotechnology, Research, Pharmaceutical, Health, Professional services, Organ systems, Human hair, Hair loss

Stemson Therapeutics announced today the closing of a DCVC Bio -led $15 million Series A financing to advance development of Stemsons proprietary therapeutic solution to cure hair loss.

Key Points: 
  • Stemson Therapeutics announced today the closing of a DCVC Bio -led $15 million Series A financing to advance development of Stemsons proprietary therapeutic solution to cure hair loss.
  • We have the technical and biological building blocks to successfully address hair loss that overcomes failures of past therapies, said Hamilton.
  • Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss.
  • Stemsons world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition.